Moreover, HER2-positive cancer is also treated with antibody-drug conjugates (ADC) that are targeted therapies that combine cytotoxic agents with monoclonal antibodies with the purpose of minimizing the toxic side effects typically associated with chemotherapy while maximizing the efficacy of the therapy [76]. This evidence concerns the gene ERBB2 and cancer.